Compare Incyte Corporation (INCY) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Southwest Airlines Co — how do they compare? Incyte Corporation trades at $120.49 (market cap $24.48B), while Southwest Airlines Co trades at $45.25 (market cap $22.00B). The key difference: Incyte Corporation and Southwest Airlines Co are close in size by market cap, and Southwest Airlines Co pays a 1.6% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | LUV | |
|---|---|---|
Market Cap | $24.48B | $22.00B |
Sector | Health | Industrials |
52-Week High | $129.93 | $54.80 |
52-Week Low | $81.66 | $29.67 |
Enterprise Value | $19.98B | $25.10B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Southwest Airlines (LUV) trades at $45.06, up 0.36% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings with $0.94 EPS beating expectations by 84%, while Q1 missed estimates. Revenue growth continues with 2026 projections at $30.1B, though net margins remain thin at 2.78%. Recent board appointments and business travel initiatives signal strategic focus on premium segments.
LUV presents a value opportunity with attractive P/S (0.79) and dividend yield, but faces headwinds from fuel cost volatility and competitive pressures. Analyst consensus targets $53.86 (20% upside) with mixed ratings. The stock's outlook hinges on sustained travel demand and effective cost management amid industry challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
